Age-Related Differences in Pulmonary Cytokine Response to Respiratory Syncytial Virus Infection: Modulation by Anti-inflammatory and Antiviral Treatment

Boukhvalova, Marina S.; Yim, Kevin C.; Kuhn, Katie H.; Hemming, John P.; Prince, Gregory A.; Porter, David D.; Blanco, Jorge C. G.
February 2007
Journal of Infectious Diseases;2/15/2007, Vol. 195 Issue 4, p511
Academic Journal
Background. Respiratory syncytial virus (RSV) is the major cause of severe lower respiratory tract infection in infants and young children. Recently, RSV has also been recognized as a serious health risk in elderly individuals, but the pathogenesis of RSV infection in elderly individuals remains unknown. Methods. Dynamics of pulmonary cytokine response (including interferon-γ, interleukin [IL]-4, IL-10, IL-6, monocyte chemoattractant protein-1, and growth-regulated oncogene [GRO] mRNA) during acute RSV infection were investigated in young (<2 months old) and aged (>9 months old) cotton rats (Sigmodon hispidus). Therapeutic treatments that diminish viral replication (antiviral antibody) and pulmonary inflammation (anti-inflammatory corticosteroid) in RSV-infected cotton rats were used to evaluate the contribution of virus replication and inflammation to the development of RSV disease with respect to age. Results. The time of the peak expression of the majority of cytokines was shifted with respect to age. Antiviral and anti-inflammatory treatments had a similar effect on cytokine expression in aged and young cotton rats. GRO mRNA transcripts were more abundant in the lungs of aged cotton rats. Conclusions. The present study reports an age-related delay in the pulmonary cytokine response to RSV and an imbalance in chemokine production with respect to age and underscores different components of RSV pathogenesis with respect to their molecular signature.


Related Articles

  • Pulmocide Attracts $27.5M Series A for Respiratory Infections. Moran, Nuala // BioWorld Today;11/26/2013, Vol. 24 Issue 228, p1 

    The article reports on the 27.5 million U.S. dollar raised by Pulmocide Ltd. in Series A funding to embark on the discovery of a new generation of inhaled treatments for serious viral and fungal infections of the respiratory tract, in November 2013. Garth Rapeport, chief executive officer (CEO)...

  • FDA approves liquid formulation of MedImmune's Synagis.  // PharmaWatch: Biotechnology;September 2004, Vol. 3 Issue 9, p13 

    Reports on the confirmation made by MedImmune that the U.S. Food and Drug Administration has approved a liquid formulation of Synagis, which was originally approved by the FDA to prevent serious lower respiratory tract disease caused by respiratory syncytial virus in pediatric patients at high...

  • The Human Cathelicidin LL-37 Has Antiviral Activity against Respiratory Syncytial Virus. Currie, Silke M.; Findlay, Emily Gwyer; McHugh, Brian J.; Mackellar, Annie; Man, Tian; Macmillan, Derek; Wang, Hongwei; Fitch, Paul M.; Schwarze, Jürgen; Davidson, Donald J. // PLoS ONE;Aug2013, Vol. 8 Issue 8, p1 

    Respiratory syncytial virus is a leading cause of lower respiratory tract illness among infants, the elderly and immunocompromised individuals. Currently, there is no effective vaccine or disease modifying treatment available and novel interventions are urgently required. Cathelicidins are...

  • ALNYLAM SUBMITS IND APPLICATION FOR ALN-RSV01 TRIAL.  // Biotech Business;Dec2005, Vol. 18 Issue 12, p8 

    Reports that Alnylam Pharmaceuticals Inc. has submitted a drug application to the U.S. Food and Drug Administration in 2005 for its ALN-RSV01 therapeutic for the treatment of patients with respiratory syncytial virus (RSV). Information on RSV; Description of RNA interference; Profile of Alnylam.

  • Respiratory syncytial virus market. Storey, Shane // Nature Reviews Drug Discovery;Jan2010, Vol. 9 Issue 1, p15 

    The article offers information about the respiratory syncytial virus (RSV) infections and the market of their treatment. These infections are considered as the primary cause of viral death in infants. It notes that the development of RSV vaccines has specific challenges with distant prospect on...

  • AAP Releases Policy Statement on the Prevention of RSV Infections. Ressel, Genevieve W. // American Family Physician;2/15/2004, Vol. 69 Issue 4, p993 

    Outlines the policy statement released by the American Academy of Pediatrics (AAP) on the revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous (RSV-IGIV) for the prevention of RSV infections. Information on how palivizumab is administered;...

  • Vitamin A for treatment of acute RSV infection. Sadovsky, Richard // American Family Physician;1/1/1997, Vol. 55 Issue 1, p282 

    Summarizes a study by J.S. Bresee, et al, which appeared in the `Pediatric Infectious Disease Journal' of 1996, volume 15, that evaluated the effectiveness of high-dose Vitamin A in the treatment of acute respiratory syncytial virus (RSV) infection. Background on the study; Outline of results;...

  • Steroids not advised after syncytial virus respiratory function.  // Nursing Standard;6/17/2009, Vol. 23 Issue 41, p16 

    The article reports on the results of research which was conducted in the Netherlands in an effort to investigate the effects of giving high dose inhaled corticosteroids to infants after a hospital admission for respiratory syncytial virus infections. Researchers examined 243 infants and found...

  • For babes in the woods. Portyansky, Elena // Drug Topics;7/20/98, Vol. 142 Issue 14, p20 

    Presents information relating to the dangers associated with the respiratory syncytial virus (RSV) on babies, while highlighting the introduction of the drug, medlmmune's synagis (palivizumab) in the treatment of the disease. Inclusion of therapeutic options available; Benefits concerning the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics